AstraZeneca Common Stock Net 2010-2024 | AZN

AstraZeneca common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
  • AstraZeneca common stock net for the quarter ending June 30, 2024 was $0.388B, a 0.26% increase year-over-year.
  • AstraZeneca common stock net for 2023 was $0.388B, a 0.26% increase from 2022.
  • AstraZeneca common stock net for 2022 was $0.387B, a 0% decline from 2021.
  • AstraZeneca common stock net for 2021 was $0.387B, a 17.99% increase from 2020.
AstraZeneca Annual Common Stock Net
(Millions of US $)
2023 $388
2022 $387
2021 $387
2020 $328
2019 $328
2018 $317
2017 $317
2016 $316
2015 $316
2014 $316
2013 $315
2012 $312
2011 $323
2010 $352
2009 $363
AstraZeneca Quarterly Common Stock Net
(Millions of US $)
2024-06-30 $388
2024-03-31 $388
2023-12-31 $388
2023-09-30 $387
2023-06-30 $387
2023-03-31 $387
2022-12-31 $387
2022-09-30 $387
2022-06-30 $387
2022-03-31 $387
2021-12-31 $387
2021-09-30 $387
2021-06-30 $328
2021-03-31 $328
2020-12-31 $328
2020-09-30 $328
2020-06-30 $328
2020-03-31 $328
2019-12-31 $328
2019-09-30 $328
2019-06-30 $328
2019-03-31 $317
2018-12-31 $317
2018-09-30 $317
2018-06-30 $317
2018-03-31 $317
2017-12-31 $317
2017-09-30 $316
2017-06-30 $316
2017-03-31 $316
2016-12-31 $316
2016-09-30 $316
2016-06-30 $316
2016-03-31 $316
2015-12-31 $316
2015-09-30 $316
2015-06-30 $316
2015-03-31 $316
2014-12-31 $316
2014-09-30 $316
2014-06-30 $316
2014-03-31 $316
2013-12-31 $315
2013-09-30 $314
2013-06-30 $313
2013-03-31 $313
2012-12-31 $312
2012-09-30 $312
2012-06-30 $315
2012-03-31 $318
2011-12-31 $323
2011-09-30 $332
2011-06-30 $341
2011-03-31 $346
2010-12-31 $352
2010-09-30 $356
2010-06-30 $360
2010-03-31 $362
2009-12-31 $363
2009-09-30 $363
2009-06-30 $362
2009-03-31 $362
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51